Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to |
(State or Other Jurisdiction of Incorporation) |
(I.R.S. Employer Identification No.) | |
|
||
(Address of principal executive offices) |
(zip code) |
Title of Each Class |
Trading Symbols |
Name of Each Exchange on Which Registered | ||
one-half of one Redeemable Warrant |
||||
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
☒ |
Smaller reporting company |
|||||
Emerging growth company |
Auditor Firm Id: |
Auditor Name: |
Auditor Location: |
• |
our ability to complete any Business Combination, whether with Apexigen or another company; |
• |
the anticipated benefits of any Business Combination, whether with Apexigen or another company; |
• |
our executive officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving a Business Combination, as a result of which they would then receive expense reimbursements or other benefits; |
• |
our potential ability to obtain additional financing, if needed, to complete a Business Combination, whether with Apexigen or another company; |
• |
our public securities’ potential liquidity and trading; |
• |
the use of proceeds not held in the trust account (as described herein) or available to us from interest income on the trust account balance; or |
• |
our financial performance. |
1 |
||||
1 |
||||
6 |
||||
52 |
||||
52 |
||||
52 |
||||
52 |
||||
53 |
||||
53 |
||||
53 | ||||
54 |
||||
60 |
||||
60 |
||||
60 |
||||
60 |
||||
61 |
||||
61 |
||||
62 |
||||
62 |
||||
71 |
||||
72 |
||||
74 |
||||
77 |
||||
79 |
||||
79 |
||||
81 |
ITEM 1. |
BUSINESS |
• | Subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and |
• | Cause us to depend on the marketing and sale of a single product or limited number of products or services. |
• | the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; |
• | the outcome of any legal proceedings that may be instituted against the Company, Apexigen or others following announcement of the business combination and the transactions contemplated in the Business Combination Agreement; |
• | the inability to complete the transactions contemplated by the Business Combination Agreement due to the failure to obtain approval of the stockholders of the Company or Apexigen or other conditions to closing in the Business Combination Agreement; |
• | the ability to obtain or maintain the listing of the Combined Company’s common stock on NASDAQ following the business combination; |
• | the risk that the proposed transaction disrupts current plans and operations as a result of the announcement and consummation of the business combination; |
• | the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, the ability of the Company to grow and manage growth profitably, maintain relationships with customers, compete within its industry and retain its key employees; |
• | costs related to the proposed business combination; |
• | changes in applicable laws or regulations; |
• | the effect of the COVID-19 pandemic on the Combined Company’s business; |
• | the ability of the Combined Company to execute its business model, including market acceptance of its planned products and services and achieving sufficient production volumes at acceptable quality levels and prices; |
• | the Combined Company’s ability to raise capital; |
• | the possibility that the Company or Apexigen may be adversely impacted by other economic, business, and/or competitive factors; |
• | future exchange and interest rates; and |
• | other risks and uncertainties indicated in this Annual Report and other filings that have been made or will be made with the SEC by the Company. |
• | a limited availability of market quotations for the Combined Company’s securities; |
• | reduced liquidity for the Combined Company’s securities; |
• | a determination that the Combined Company’s common stock is a “penny stock” which will require brokers trading in the Combined Company’s common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of the Combined Company’s common stock; |
• | a limited amount of analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | the Company may experience negative reactions from the financial markets, including negative impacts on the stock price of shares of the Company Common Stock (including to the extent that the current market price reflects a market assumption that the Business Combination will be completed); |
• | the Company will have incurred substantial expenses and will be required to pay certain costs relating to the Business Combination, whether or not the Business Combination is completed; and |
• | since the Business Combination Agreement restricts the conduct of the Company’s businesses prior to completion of the Business Combination, the Company may not have been able to take certain actions during the pendency of the Business Combination that would have benefitted it as an independent company, and the opportunity to take such actions may no longer be available. |
• | If the Business Combination with Apexigen or another business combination is not consummated within the time required by the Company’s charter, the Company will cease all operations except for |
the purpose of winding up, redeeming 100% of the outstanding Public Shares for cash and, subject to the approval of its remaining stockholders and the Board, dissolving and liquidating. In such event, the 1,437,500 Founder Shares held by the Sponsor, which were acquired for a purchase price of approximately $0.017 per share, would be worthless because holders of the Founder Shares are not entitled to participate in any redemption or distribution with respect to such shares. The Founder Shares held by the Sponsor had an aggregate market value of $14,461,250 based upon the closing price of $10.06 per share of the Company Common Stock on the NASDAQ on March 30, 2022. |
• | Given the differential in the purchase price that our Sponsor paid for the Founder Shares as compared to the price of the Company units sold in the IPO and the substantial number of shares of Combined Company common stock that our Sponsor will receive upon conversion of the Founder Shares in connection with the Business Combination, our Sponsor and its affiliates may earn a positive rate of return on their investment even if the Combined Company common stock trades below the price initially paid for the Company units in the IPO and the Public Stockholders experience a negative rate of return following the completion of the Business Combination. Thus, our Sponsor and its affiliates may have more of an economic incentive for us to, rather than liquidate if we fail to complete our initial business combination by the time required under our charter (May 2, 2022), enter into an initial business combination on potentially less favorable terms with a potentially less favorable, riskier, weaker-performing or financially unstable business, or an entity lacking an established record of revenues or earnings, than would be the case if such parties had paid the full offering price for their Founder Shares. The Company has called a special meeting of its stockholders for April 26, 2022, for purposes of requesting the approval of holders of 65% of the Company’s outstanding shares of common stock to extend the date by which the initial business combination be completed on a monthly basis for up to six months to November 2, 2022. |
• | The Sponsor purchased an aggregate of 247,000 placement units from the Company for an aggregate purchase price of $2,470,000 (or $10.00 per unit). This purchase took place on a private placement basis simultaneously with the consummation of the IPO. A portion of the proceeds the Company received from this purchase were placed in the Trust Account. Each unit included one-half warrant to purchase a share of common stock. Such warrants had an aggregate market value of approximately $54,340 based upon the closing price of $0.44 per warrant on the NASDAQ on March 30, 2022, the Record Date. The placement units will become worthless if the Company does not consummate a business combination within period mandated under our charter. |
• | Samuel P. Wertheimer will become a director of the Post-Combination Company after the Closing. As such, in the future he may receive any cash fees, stock options or stock awards that the Board determines to pay to its directors. |
• | The Company’s directors and officers, and their affiliates are entitled to reimbursement of out-of-pocket |
• | The continued indemnification of current directors and officers and the continuation of directors’ and officers’ liability insurance. |
• | In the event of the liquidation of the Trust Account, the Sponsor has agreed to indemnify and hold harmless the Company against any and all losses, liabilities, claims, damages and expenses to which the Company may become subject as a result of any claim by (i) any third party for services rendered |
or products sold to the Company or (ii) a prospective target business with which the Company has entered into an acquisition agreement, provided that such indemnification of the Company by the Sponsor shall apply only to the extent necessary to ensure that such claims by a third party for services rendered or products sold to the Company or a target do not reduce the amount of funds in the Trust Account to below (i) $10.00 per share of the common stock or (ii) such lesser amount per share of the common stock held in the Trust Account due to reductions in the value of the trust assets as of the date of the liquidation of the Trust Account, in each case, net of the amount of interest earned on the property in the Trust Account, which may be withdrawn to pay taxes and expenses related to the administration of the Trust Account, except as to any claims by a third party (including a target) who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. If the Company consummates the Business Combination, on the other hand, the Company will be liable for all such claims. |
• | The Sponsor has agreed not to transfer, assign, or sell any of its Founder Shares until 180 days following the consummation of the Business Combination, subject to certain customary exceptions. |
• | Subject to certain limited exceptions, the placement units will not be transferable until 30 days following the completion of the Business Combination. |
• | There will be no finder’s fees, reimbursements or cash payments made by the Company to the Sponsor or the Company’s officers or directors, or the Company’s or any of their affiliates, for services rendered to the Company prior to or in connection with the completion of the Business Combination, other than payment of the amount described above for office space, utilities, administrative and support services described above. The Sponsor and the Company’s officers and directors or any of their respective affiliates will also be reimbursed for any out-of-pocket out-of-pocket |
• | the impact of the COVID-19 pandemic on our financial condition and the results of operations; |
• | our operating and financial performance and prospects; |
• | our quarterly or annual earnings or those of other companies in our industry compared to market expectations; |
• | conditions that impact demand for our products and/or services; |
• | future announcements concerning our business, our clients’ businesses or our competitors’ businesses; |
• | the public’s reaction to our press releases, other public announcements and filings with the SEC; |
• | the market’s reaction to our reduced disclosure and other requirements as a result of being an “emerging growth company” under the Jumpstart Our Business Startups Act (the “JOBS Act”); |
• | the size of our public float; |
• | coverage by or changes in financial estimates by securities analysts or failure to meet their expectations; |
• | market and industry perception of our success, or lack thereof, in pursuing our growth strategy; |
• | strategic actions by us or our competitors, such as acquisitions or restructurings; |
• | changes in laws or regulations which adversely affect our industry or us; |
• | privacy and data protection laws, privacy or data breaches, or the loss of data; |
• | changes in accounting standards, policies, guidance, interpretations or principles; |
• | changes in senior management or key personnel; |
• | issuances, exchanges or sales, or expected issuances, exchanges or sales of our capital stock; |
• | changes in our dividend policy; |
• | adverse resolution of new or pending litigation against us; and |
• | changes in general market, economic and political conditions in the United States and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war and responses to such events. |
• | a staggered board, which means that the Combined Company Board will be classified into three classes of directors with staggered three-year terms and directors will only be able to be removed from office for cause; |
• | limitations on convening special stockholder meetings, which could make it difficult for our stockholders to adopt desired governance changes; |
• | a prohibition on stockholder action by written consent, which means that our stockholders will only be able to take action at a meeting of stockholders and will not be able to take action by written consent for any matter; |
• | a forum selection clause, which means certain litigation against us can only be brought in Delaware; |
• | the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without further action by our stockholders; and |
• | advance notice procedures, which apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders. |
• | solely dependent upon the performance of a single business, property or asset, or |
• | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
• | restrictions on the nature of our investments; and |
• | restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. |
• | registration as an investment company; |
• | adoption of a specific form of corporate structure; and |
• | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
• | our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
• | our inability to pay dividends on our common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and |
• | other disadvantages compared to our competitors who have less debt. |
• | may significantly dilute the equity interest of investors in this offering; |
• | may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
• | may adversely affect prevailing market prices for our units, common stock and/or warrants. |
(i) | we issue additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a Newly Issued Price of less than $9.20 per share; |
(ii) | the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and |
(iii) | the Market Value is below $9.20 per share, |
• | Competition could reduce profit margins. |
• | Our inability to comply with governmental regulations affecting the life sciences industry could negatively affect our operations. |
• | An inability to license or enforce intellectual property rights on which our business may depend. |
• | The success of our planned business following consummation of our initial business combination may depend on maintaining a well-secured business and technology infrastructure. |
• | If we are required to obtain governmental approval of our products, the production of our products could be delayed and we could be required to engage in a lengthy and expensive approval process that may not ultimately be successful. |
• | Continuing government and private efforts to contain healthcare costs, including through the implementation of legal and regulatory changes, may reduce our future revenue and our profitability following such business combination. |
• | Changes in the life sciences industry and markets for such products affecting our customers or retailing practices could negatively impact customer relationships and our results of operations. |
• | The life sciences industry is susceptible to significant liability exposure. If liability claims are brought against us following a business combination, it could materially adversely affect our operations. |
• | Dependence of our operations upon third-party suppliers, manufacturers or contractors whose failure to perform adequately could disrupt our business. |
• | The Affordable Care Act, possible changes to it, and how it is implemented could negatively impact our business. |
• | A disruption in supply could adversely impact our business. |
Units (BCACU) |
Common Stock (BCAC) |
Warrants (BCACW) |
||||||||||||||||||||||
High |
Low |
High |
Low |
High |
Low |
|||||||||||||||||||
Year ended December 31, 2021: |
||||||||||||||||||||||||
Quarter ended March 31, 2021 (1) |
$ | 12.45 | $ | 10.29 | $ | 11.07 | $ | 9.11 | $ | 5.46 | $ | 1.46 | ||||||||||||
Quarter ended June 30, 2021 |
$ | 11.00 | $ | 10.51 | $ | 9.99 | $ | 9.76 | $ | 2.00 | $ | 1.25 | ||||||||||||
Quarter ended September 30, 2021 |
$ | 11.00 | $ | 9.76 | $ | 10.00 | $ | 9.80 | $ | 1.902 | $ | 0.62 | ||||||||||||
Quarter ended December 31, 2021 |
$ | 10.45 | $ | 9.76 | $ | 10.03 | $ | 9.91 | $ | 1.03 | $ | 0.39 |
(1) | Beginning on February 3, 2021, with respect to BCACU and February 22, 2021 with respect to BCAC and BCACW. |
ITEM 10. |
OFFICERS, DIRECTORS AND DIRECTOR NOMINEES |
Name |
Age |
Position | ||||
Dr. Samuel P. Wertheimer |
62 | Chief Executive Officer and Chairman | ||||
Scott A Katzmann |
66 | President and Director Nominee | ||||
Patrick A. Sturgeon |
45 | Chief Financial Officer | ||||
James N. Hauslein |
62 | Director Nominee | ||||
Elgar Peerschke |
65 | Director Nominee | ||||
Tito A. Serafini, PhD |
58 | Director Nominee |
• | the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by us; |
• | pre-approving all audit and permitted non-audit services to be provided by the independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; |
• | setting clear hiring policies for employees or former employees of the independent registered public accounting firm, including but not limited to, as required by applicable laws and regulations; |
• | setting clear policies for audit partner rotation in compliance with applicable laws and regulations; |
• | obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public accounting firm’s internal quality-control procedures, (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues and (iii) all relationships between the independent registered public accounting firm and us to assess the independent registered public accounting firm’s independence; |
• | reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and |
• | reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
• | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, if any is paid by us, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
• | reviewing and approving on an annual basis the compensation, if any is paid by us, of all of our other officers; |
• | reviewing on an annual basis our executive compensation policies and plans; |
• | implementing and administering our incentive compensation equity-based remuneration plans; |
• | assisting management in complying with our proxy statement and annual report disclosure requirements; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; |
• | if required, producing a report on executive compensation to be included in our annual proxy statement; and |
• | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
• | None of our officers or directors is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest in allocating his or her time among various business activities. |
• | In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to us as well as the other entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
• | Our initial stockholders have agreed to waive their redemption rights with respect to any founder shares or representative shares, as applicable, and placement shares and (except for Ladenburg) any public shares held by them in connection with the consummation of our initial business combination. Additionally, our initial stockholders have agreed to waive their redemption rights with respect to any founder shares or representative shares, as applicable, and placement shares held by them if we fail to consummate our initial business combination within 15 months after the closing of this offering. If we do not complete our initial business combination within such applicable time period, the proceeds of the sale of the placement units held in the trust account will be used to fund the redemption of our public shares, and the placement securities will expire worthless. With certain limited exceptions, our sponsor has agreed not to transfer, assign or sell 50% of their founder shares until the earlier of (i) six months after the date of the consummation of our initial business combination or (ii) the date on which the closing price of our shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after our initial business combination, and the remaining 50% of the founder shares may not be transferred, assigned or sold until six months after the date of the |
consummation of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property. With certain limited exceptions, the placement shares and placement warrants and the common stock underlying such warrants, and the representative shares held by Ladenburg and its employees, will not be transferable, assignable or saleable by our sponsor or its permitted transferees or Ladenburg or its employees and permitted transferees until 30 days after the completion of our initial business combination. Since our sponsor and officers and directors may directly or indirectly own common stock and warrants following this offering, our officers and directors may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. |
• | Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. |
• | We may pay Brookline or its affiliates, partners or employees, a fee for financial advisory services rendered in connection with our identification, negotiation and consummation of our initial business combination. The amount of any fee we pay to Brookline or its affiliates, partners or employees, will be based upon the prevailing market for similar services for such transactions at such time, and will be subject to the review of our audit committee pursuant to the audit committee’s policies and procedures relating to transactions that may present conflicts of interest. |
• | Our sponsor, officers or directors may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our sponsor or an affiliate of our sponsor or any of our officers or directors to finance transaction costs in connection with an intended initial business combination. Up to $1,500,000 of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation of our initial business combination. The units would be identical to the placement units. |
• | the corporation could financially undertake the opportunity; |
• | the opportunity is within the corporation’s line of business; and |
• | it would not be fair to our company and its stockholders for the opportunity not to be brought to the attention of the corporation. |
Individual (1) |
Entity |
Entity’s Business |
Affiliation | |||
Scott A. Katzmann |
Brookline Capital Markets |
Investment Bank |
Founder | |||
Dr. Samuel P. Werthmeimer |
Brookline Capital Markets |
Investment Bank |
Managing Partner | |||
Patrick A. Sturgeon |
Brookline Capital Markets |
Investment Bank |
Managing Partner | |||
|
Alpha Healthcare Acquisition Corp. |
Blank Check Company |
Officer | |||
James N. Hauslein |
Hauslein & Company |
Investing |
Managing Director | |||
|
Jupiter Acquisition Corp |
Blank Check Company |
Officer and Director | |||
Elgar Peerschke |
ARdVRk Technologies |
Healthcare and Life Sciences |
Director | |||
Tito A. Serafini, PhD |
Atreca |
Biotechnology |
Officer and Director |
(1) | Each person has a fiduciary duty with respect to the listed entities next to their respective names. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
• | each of our executive officers, directors and director nominees that beneficially owns shares of our common stock; and |
• | all our executive officers, directors and director nominees as a group. |
Name and Address of Beneficial Owner() |
Number of Shares Beneficially Owned (2) |
Approximate Percentage of Outstanding Common Stock |
||||||
Brookline Capital Holdings, LLC (2) |
1,428,250 | 19.2 | % | |||||
Dr. Samuel P. Wertheimer (2) |
— | — | ||||||
Scott A Katzmann (2) |
— | — | ||||||
Patrick A. Sturgeon (2) |
— | — | ||||||
James N. Hauslein (2) |
— | — | ||||||
Elgar Peerschke (2) |
— | — | ||||||
Tito A. Serafini, PhD (2) |
— | — | ||||||
All executive officers and directors as a group (6 individuals) (1) |
1,428,250 | 19.2 | % | |||||
Periscope Capital Inc. (3) |
417,000 | 5.6 | % | |||||
Kepos Capital LP (4) |
382,289 | 5.1 | % |
• | Less than 1% |
(1) | The business address of each of these entities and individuals is at 280 Park Avenue, Suite 43W, New York, NY 10017. |
(2) | Interests shown consist solely of Private Shares as well as the Private Shares that are a constituent part of the Private Placement Units. Brookline Capital Holdings, LLC, our Sponsor, is the record holder of the shares reported herein. William Buchanan, Jr. is the managing member of our Sponsor. Consequently, such person may be deemed the beneficial owner of the shares held by our Sponsor and have voting and |
dispositive control over such securities. Such person disclaims beneficial ownership of any shares other than to the extent he may have a pecuniary interest therein, directly or indirectly. Each of our officers, directors and advisors is a direct or indirect member of our Sponsor. |
(3) | Based on the Form 13G filed by Periscope Capital Inc., as filed with the SEC on February 14, 2022. The business address reported is 333 Bay Street, Suite 1240, Toronto, Ontario, Canada M5H 2R2. |
(4) | Based on the Form 13G filed by Kepos Capital LP, as filed with the SEC on February 4, 2022. Mr. Mark Carhart is reported as the managing partner of Kepos Capital GP LLC, the general partner of Kepos Capital LP. The business address reported is 11 Time Square, 35th Floor, New York, NY 10036. |
• | Repayment of up to an aggregate of $300,000 in loans made to us by our sponsor to cover offering-related and organizational expenses; |
• | Payment to an affiliate of our sponsor of $10,000 per month, for up to 15 months, for office space, utilities and secretarial and administrative support; |
• | Payment of a fee of $25,000 to our Chief Financial Officer, Patrick Sturgeon, in February 2021 in consideration for financial advisory services provided to the Company since our inception. |
• | We may pay Brookline or its affiliates, partners or employees, a fee for financial advisory services rendered in connection with our identification, negotiation and consummation of our initial business combination; the amount of any fee we pay Brookline or its affiliates, partners or employees, will be based upon the prevailing market for similar services for such transactions at such time, and will be subject to the review of our audit committee pursuant to the audit committee’s policies and procedures relating to transactions that may present conflicts of interest; |
• | Reimbursement for any out-of-pocket expenses |
• | Repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination, the terms of which have not been determined nor have any written agreements been executed with respect thereto. Up to $1,500,000 of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation of our initial business combination. The units would be identical to the placement units. |
(1) | Financial Statements: |
Page |
||||
F-2 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
(2) | Financial Statement Schedules: |
(3) | Exhibits |
32.1†† | Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
99.1 | Form of Audit Committee Charter (incorporated by reference to Exhibit 99.1 filed on the Company’s Registration Statement on Form S-1/A filed by the Company on August 24, 2020) | |
99.2 | Form of Compensation Committee Charter (incorporated by reference to Exhibit 99.2 filed on the Company’s Registration Statement on Form S-1/A filed by the Company on August 24, 2020) | |
101.INS* | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
† | Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. |
†† | Furnished herewith. |
* | Filed herewith. |
** | Filed with the Company’s Form S-1/A filed with the SEC on January 31, 2021. |
*** | Incorporated by reference to the Form 8-K filed by the Company with the SEC on March 18, 2022. |
BROOKLINE CAPITAL ACQUISITION CORP. | ||
By: | /s/ Dr. Samuel P. Wertheimer | |
Name: Dr. Samuel P. Wertheimer Title: Chairman of the Board and Chief Executive Officer |
Name |
Position |
Date | ||
/s/ Dr. Samuel P. Wertheimer Dr. Samuel P. Wertheimer |
Chief Executive Officer and Chairman (principal executive officer) |
April 7, 2022 | ||
/s/ Patrick A. Sturgeon Patrick A. Sturgeon |
Chief Financial Officer (principal financial and accounting officer) |
April 7, 2022 |
Name |
Title |
Date | ||
/s/ Samuel P. Wertheimer Samuel P. Wertheimer |
Chief Executive Officer and Chairman |
April 7, 2022 | ||
/s/ Scott A. Katzmann Scott A. Katzmann |
President and Director Nominee |
April 7, 2022 | ||
/s/ Patrick A. Sturgeon Patrick A. Sturgeon |
Chief Financial Officer |
April 7, 2022 | ||
/s/ James N. Hauslein James N. Hauslein |
Director Nominee |
April 7, 2022 | ||
/s/ Elgar Peerschke Elgar Peerschke |
Director Nominee |
April 7, 2022 | ||
/s/ Tito A. Serafini, PhD Tito A. Serafini, PhD |
Director Nominee |
April 7, 2022 |
Page |
||||
F-2 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
December 31, |
||||||||
2021 |
2020 |
|||||||
Assets: |
||||||||
Current assets: |
||||||||
Cash |
$ | $ | ||||||
Prepaid expenses |
— | |||||||
|
|
|
|
|||||
Total current assets |
||||||||
Investments held in Trust Account |
— | |||||||
Deferred offering costs associated with the proposed public offering |
— | |||||||
|
|
|
|
|||||
Total Assets |
$ |
$ |
||||||
|
|
|
|
|||||
Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Equity: |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | — | |||||
Accrued expenses |
— | |||||||
Franchise tax payable |
— | |||||||
Note payable — related party |
— | |||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Derivative warrant liabilities |
— | |||||||
|
|
|
|
|||||
Total liabilities |
||||||||
Commitments and Contingencies |
||||||||
Common stock subject to possible redemption ; redemption value of $ |
— | |||||||
Stockholders’ Equity: |
||||||||
Preferred stock, $ |
||||||||
Common stock, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Equity |
$ |
$ |
||||||
|
|
|
|
For the year ended December 31, 2021 |
For the period from May 27, 2020 (inception) through December 31, 2020 |
|||||||
General and administrative expenses |
$ | $ | ||||||
Administrative expenses — related party |
— | |||||||
Franchise tax expense |
— | |||||||
Loss from operations |
( |
) | ( |
) | ||||
Other income (expense) |
||||||||
Change in fair value of derivative warrant liabilities |
— | |||||||
Offering costs allocated to private warrants |
( |
) |
— |
|||||
Net gain from investments held in Trust Account |
— | |||||||
Total other income |
— | |||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Weighted average shares outstanding — redeemable common stock |
— | |||||||
Basic and diluted net loss per share, redeemable common stock |
$ | ( |
) | $ | — | |||
Weighted average shares outstanding — non-redeemable common stock |
||||||||
Basic and diluted net loss per share, non-redeemable common stock |
$ | ( |
) | $ | ( |
) | ||
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance — May 27, 2020 (inception) |
— |
$ |
$ |
$ |
$ |
|||||||||||||||
Issuance of common stock to Sponsor |
— |
|||||||||||||||||||
Sponsor forfeiture of founder shares |
( |
) | ( |
) | — |
— |
||||||||||||||
Issuance of founder shares to affiliates of underwriter |
— |
|||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance — December 31, 2020 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance — December 31, 2020 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Fair value of public warrants included in the units sold in the initial public offering |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
Capital contribution from Sponsor |
— |
— |
— |
|||||||||||||||||
Offering costs associated with public warrants |
|
|
— |
|
|
|
— |
|
|
|
( |
) | |
|
— |
|
|
|
( |
) |
Sale of units in private placement, less derivative warrant liabilities |
— |
|||||||||||||||||||
Remeasurement of common stock subject to possible redemption |
— | — | ( |
) | — | ( |
) | |||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
Balance — December 31, 2021 |
$ |
$ |
$ |
( |
) | $ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2021 |
For the period from May 27, 2020 (inception) through December 31, 2020 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
General and administrative expenses paid by related party under promissory note |
||||||||
Change in fair value of derivative warrant liabilities |
( |
) | — | |||||
Offering costs allocated to private warrants |
— |
|||||||
Net gain from investments held in Trust Account |
( |
) | — | |||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
( |
) | — | |||||
Account payable |
— | |||||||
Accrued expenses |
— | |||||||
Franchise tax payable |
— | |||||||
Net cash used in operating activities |
( |
) | — | |||||
Cash Flows from Investing Activities |
||||||||
Cash deposited in Trust Account |
( |
) | — | |||||
Net cash used in investing activities |
( |
) | — | |||||
Cash Flows from Financing Activities: |
||||||||
Repayment of note payable to related party |
( |
) | — | |||||
Proceeds from issuance of representative shares |
— | |||||||
Proceeds received from initial public offering, gross |
— | |||||||
Proceeds received from private placement |
— | |||||||
Offering costs paid |
( |
) | — | |||||
Net cash provided by financing activities |
||||||||
Net change in cash |
||||||||
Cash — beginning of the period |
||||||||
Cash — end of the period |
$ |
$ | ||||||
Supplemental disclosure of noncash activities: |
||||||||
Offering costs included in accrued expenses |
$ | $ | — | |||||
Offering costs paid by related party under promissory note |
$ | $ | ||||||
Deferred offering costs paid by Sponsor in exchange for common stock |
$ | — | $ | |||||
Remeasurement of common stock subject to possible redemption |
$ |
$ |
— |
|||||
• | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For the year ended December 31, 2021 |
For the period from May 27, 2020 (inception) through December 31, 2020 |
|||||||||||
redeemable |
non-redeemable |
non-redeemable |
||||||||||
Basic and diluted net loss per common share: |
||||||||||||
Numerator: |
||||||||||||
Allocation of net loss |
( |
) | ( |
) | ( |
) | ||||||
Denominator: |
||||||||||||
Basic and diluted weighted average common shares outstanding |
||||||||||||
|
|
|
|
|
|
|||||||
Basic and diluted net loss per common share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of |
• | if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any |
|
• | if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such Public Warrants at the time of redemption and for the entire 30 -day |
Gross proceeds |
$ | |||
Less: |
||||
Proceeds allocated to public warrants |
|
|
( |
) |
Common stock issuance costs |
( |
) | ||
Plus: |
||||
Remeasurement of carrying value to redemption value |
||||
|
|
|||
Common stock subject to possible redemption |
$ | |||
|
|
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets — Investments held in Trust Account: |
||||||||||||
Mutual funds |
$ | $ | — | $ | — | |||||||
U.S. Treasury Securities |
$ | $ | — | $ | — | |||||||
Liabilities: |
||||||||||||
Derivative warrant liabilities — Private |
$ | — | $ | — | $ |
As of February 2, 2021 |
As of December 31, 2021 |
|||||||
Volatility |
% |
% | ||||||
Stock price |
$ |
$ |
||||||
Expected life of the options to convert |
||||||||
Risk-free rate |
% |
% | ||||||
Dividend yield |
% |
% |
Level 3 — Derivative warrant liabilities at January 1, 2021 |
$ | |||
Issuance of Private Warrants |
||||
Change in fair value of derivative warrant liabilities |
( |
) | ||
|
|
|||
Level 3 — Derivative warrant liabilities at December 31, 2021 |
$ | |||
|
|
December 31, 2021 |
||||
Current |
||||
Federal |
$ | |||
State |
||||
Deferred |
||||
Federal |
( |
) | ||
State |
||||
Valuation allowance |
||||
|
|
|||
Income tax provision |
$ | — | ||
|
|
December 31, 2021 |
||||
Deferred tax assets: |
||||
Start-up/Organization costs |
$ | |||
Net operating loss carryforwards |
||||
|
|
|||
Total deferred tax assets |
||||
Valuation allowance |
( |
) | ||
|
|
|||
Deferred tax asset, net of allowance |
$ | |||
|
|
December 31, 2021 |
||||
Statutory Federal income tax rate |
% | |||
Meals & entertainment |
% | |||
Financing costs |
% | |||
Change in fair value of warrant liabilities |
% | |||
Change in Valuation Allowance |
( |
)% | ||
|
|
|||
Income Taxes Benefit |
% | |||
|
|